Geode Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.7M	Buy	12,275,084 +1,340,832	+12%	+$5.18M	﹤0.01%	1653
2025 Q4	$44.7M	Buy	10,934,252 +1,310,695	+14%	+$6.49M	﹤0.01%	1556
2025 Q3	$47M	Buy	9,623,557 +1,847,149	+24%	+$9.7M	﹤0.01%	1501
2025 Q2	$39.4M	Buy	7,776,408 +1,332,428	+21%	+$6.55M	﹤0.01%	1555
2025 Q1	$34.1M	Buy	6,443,980 +356,831	+6%	+$2.6M	﹤0.01%	1596
2024 Q4	$41.2M	Buy	6,087,149 +655,238	+12%	+$4.41M	﹤0.01%	1553
2024 Q3	$35.8M	Buy	5,431,911 +656,003	+14%	+$4.7M	﹤0.01%	1649
2024 Q2	$35.8M	Buy	4,775,908 +1,324,743	+38%	+$11.6M	﹤0.01%	1583
2024 Q1	$34.4M	Buy	3,451,165 +125,180	+4%	+$1.39M	﹤0.01%	1601
2023 Q4	$32.8M	Buy	3,325,985 +187,295	+6%	+$1.34M	﹤0.01%	1618
2023 Q3	$24M	Buy	3,138,690 +329,547	+12%	+$3.29M	﹤0.01%	1706
2023 Q2	$21M	Buy	2,809,143 +65,659	+2%	+$459K	﹤0.01%	1821
2023 Q1	$18.3M	Buy	2,743,484 +133,536	+5%	+$1.06M	﹤0.01%	1866
2022 Q4	$20.1M	Buy	2,609,948 +277,865	+12%	+$2.72M	﹤0.01%	1768
2022 Q3	$24.8M	Buy	2,332,083 +826,087	+55%	+$8.37M	﹤0.01%	1575
2022 Q2	$12.3M	Buy	1,505,996 +212,240	+16%	+$1.42M	﹤0.01%	2115
2022 Q1	$9.26M	Sell	1,293,756 -1,201	-0.1%	-$12.8K	﹤0.01%	2394
2021 Q4	$22.2M	Buy	1,294,957 +732,626	+130%	+$13.8M	﹤0.01%	1885
2021 Q3	$12.9M	Buy	562,331 +65,382	+13%	+$1.85M	﹤0.01%	2272
2021 Q2	$18.1M	Buy	+496,949	New	+$14.7M	﹤0.01%	2034